🥴_老虎社区_美港股上老虎

Gabrielle_20
2022-01-21

🥴

UBS cuts BioNTech price target by 43% saying pandemic trade premium is fading

While still maintaining BioNTech (NASDAQ:BNTX) at neutral, UBS has cut its price target to $170 from

UBS cuts BioNTech price target by 43% saying pandemic trade premium is fading

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":630887677,"tweetId":"630887677","gmtCreate":1642775889577,"gmtModify":1642775889738,"author":{"id":3569531614182731,"authorId":3569531614182731,"authorIdStr":"3569531614182731","name":"Gabrielle_20","avatar":"https://static.tigerbbs.com/3687c03e4fcd937f9b3fa40fa7705b14","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>🥴</p></body></html>","htmlText":"<html><head></head><body><p>🥴</p></body></html>","text":"🥴","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/630887677","repostId":1125663172,"repostType":4,"repost":{"id":"1125663172","pubTimestamp":1642774815,"share":"https://www.laohu8.com/m/news/1125663172?lang=&edition=full","pubTime":"2022-01-21 22:20","market":"us","language":"en","title":"UBS cuts BioNTech price target by 43% saying pandemic trade premium is fading","url":"https://stock-news.laohu8.com/highlight/detail?id=1125663172","media":"Seeking Alpha","summary":"While still maintaining BioNTech (NASDAQ:BNTX) at neutral, UBS has cut its price target to $170 from","content":"<html><head></head><body><p>While still maintaining BioNTech (NASDAQ:BNTX) at neutral, UBS has cut its price target to $170 from $300 (~9% upside based on yesterday&#39;s close).</p><p>Analyst Eliana Merle said that with BioNTech shares down ~40% year to date, &#34;we think the recent move hints at a return to fundamentals after a highly volatile &#39;21.&#34;</p><p>Another big question for the company is what COVID-19 will be like once it becomes endemic and how that will impact the market for vaccine boosters, she notes.</p><p>&#34;Key swing factors include: the durability of long-term immunity, novel variants, severity of reinfection, competitor COVID-19 vaccines and long-term pricing,&#34; Merle writes. &#34;We think the move to omicron specific vaccines is likely and will drive demand, though questions on whether further boosters beyond an omicron booster may follow,&#34; Merle writes.</p><p>She notes that the company&#39;s pipeline is also too early &#34;to move the needle for shares in &#39;22.&#34;</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS cuts BioNTech price target by 43% saying pandemic trade premium is fading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS cuts BioNTech price target by 43% saying pandemic trade premium is fading\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-21 22:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3790287-ubs-cuts-biontech-price-target-by-43-saying-pandemic-trade-premium-is-fading><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While still maintaining BioNTech (NASDAQ:BNTX) at neutral, UBS has cut its price target to $170 from $300 (~9% upside based on yesterday's close).Analyst Eliana Merle said that with BioNTech shares ...</p>\n\n<a href=\"https://seekingalpha.com/news/3790287-ubs-cuts-biontech-price-target-by-43-saying-pandemic-trade-premium-is-fading\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://seekingalpha.com/news/3790287-ubs-cuts-biontech-price-target-by-43-saying-pandemic-trade-premium-is-fading","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125663172","content_text":"While still maintaining BioNTech (NASDAQ:BNTX) at neutral, UBS has cut its price target to $170 from $300 (~9% upside based on yesterday's close).Analyst Eliana Merle said that with BioNTech shares down ~40% year to date, \"we think the recent move hints at a return to fundamentals after a highly volatile '21.\"Another big question for the company is what COVID-19 will be like once it becomes endemic and how that will impact the market for vaccine boosters, she notes.\"Key swing factors include: the durability of long-term immunity, novel variants, severity of reinfection, competitor COVID-19 vaccines and long-term pricing,\" Merle writes. \"We think the move to omicron specific vaccines is likely and will drive demand, though questions on whether further boosters beyond an omicron booster may follow,\" Merle writes.She notes that the company's pipeline is also too early \"to move the needle for shares in '22.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":529,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}